Chadds Ford, PA, United States of America

Chunhong He

USPTO Granted Patents = 72 (Patent Applications = 18)

CIPO Patents = 11 (Patent Applications = 7)

EPO Patents = 26 (Patent Applications = 31)

Average Co-Inventor Count = 5.5

ph-index = 21

Forward Citations = 981(Granted Patents)

Forward Citations (Not Self Cited) = 699(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Boothwyn, CN (2015)
Chadds Ford, PA (US) (2013 - 2022)
Wilmington, DE (US) (2023)
Boothwyn, PA (US) (2007 - 2024)

Company Filing History:

Incyte Holdings Corporation

Bristol-myers Squibb Compnay

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

72 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12466822 - Heterocyclic compounds as immunomodulators (2025-11-11),

2. 12441727 - Tricyclic compounds as inhibitors of KRAS (2025-10-14),

3. 12415809 - Pyrrolotriazine compounds as tam inhibitors (2025-09-16),

4. 12201636 - Heterocyclylamines as PI3K inhibitors (2025-01-21),

5. 12084449 - Imidazotriazines and imidazopyrimidines as kinase inhibitors (2024-09-10),

6. 12084430 - Tricyclic urea compounds as JAK2 V617F inhibitors (2024-09-10),

7. 12030889 - Imidazopyridazine and imidazopyridine compounds and uses thereof (2024-07-09),

8. 11840534 - Substituted tricyclic compounds as FGFR inhibitors (2023-12-12),

9. 11673894 - Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors (2023-06-13),

10. 11591338 - Pyrrolotriazine compounds as TAM inhibitors (2023-02-28),

11. 11530214 - Bicyclic heterocycles as FGFR inhibitors (2022-12-20),

12. 11459329 - Imidazopyridazine and imidazopyridine compounds and uses thereof (2022-10-04),

13. 11433071 - Heterocyclylamines as PI3K inhibitors (2022-09-06),

14. 11401272 - Heterocyclic compounds as LSD1 inhibitors (2022-08-02),

15. 11261191 - Imidazotriaines and imidazopyrimidines as kinase inhibitors (2022-03-01),

Title: Innovations and Contributions of Chunhong He in Pharmaceutical Patents

Introduction: Chunhong He, a prominent inventor based in Chadds Ford, PA, has made significant strides in the field of pharmaceuticals with a remarkable portfolio of 69 patents. His work primarily focuses on the development of novel compounds that target specific biochemical pathways, showcasing his dedication to advancing medical science and innovation.

Latest Patents: Among his latest patents, Chunhong He has contributed innovative compounds such as heterocyclylamines that serve as PI3K inhibitors. These heterocyclylamine derivatives are designed to modulate the activity of phosphoinositide 3-kinases, offering potential treatments for a variety of diseases including inflammatory disorders, immune-based disorders, and cancer. Another notable patent includes imidazotriazines and imidazopyrimidines, which act as kinase inhibitors. These compounds show promise in treating cancers and other conditions linked to abnormal kinase pathway regulation.

Career Highlights: Chunhong He's extensive career includes valuable experience with reputable companies such as Incyte Corporation and Incyte Holdings Corporation. His work in these organizations has been pivotal in pushing forward cutting-edge research and development in the pharmaceutical industry.

Collaborations: Throughout his career, Chunhong He has collaborated with esteemed colleagues including Wenqing Yao and Colin Zhang. These partnerships reflect his commitment to teamwork and the sharing of expertise for the advancement of innovative solutions in medicine.

Conclusion: Chunhong He stands out as a significant figure in the realm of pharmaceutical inventions, with numerous patents highlighting his innovative spirit and scientific contributions. His work continues to impact the treatment of various diseases, paving the way for future advancements in the pharmaceutical field.

This text is generated by artificial intelligence and may not be accurate.